Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recent Developments in LRRK2-Targeted Therapy for Parkinson’s Disease

3 Jun 2019

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Parkinson's Disease Mechanisms and Treatments
Share to Plant Gene Expression Analysis

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 31161537
DOI: 10.1007/s40265-019-01139-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recent Developments in LRRK2-Targeted Therapy for Parkinson’s DiseasePMID 31161537Read ↗

LRRK2-targeted Parkinson disease drug advances into phase IIISemantic proximity Read ↗

LRRK2 in Parkinson disease: challenges of clinical trialsSemantic proximity Read ↗

LRRK2 inhibitor progresses for Parkinson disease.Semantic proximity Read ↗

Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson’s diseaseSemantic proximity Read ↗

A step forward for LRRK2 inhibitors in Parkinson's disease.Semantic proximity Read ↗

Exploring LRRK2-dependent Mechanisms in Parkinson's Disease Therapy.Semantic proximity Read ↗

Leucine-Rich Repeat Kinase 2 in Parkinson’s Disease: Updated from Pathogenesis to Potential Therapeutic TargetSemantic proximity Read ↗

Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.Semantic proximity Read ↗

Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson’s disease: a patent review of the literature to dateSemantic proximity Read ↗

Targeting LRRK2 in Parkinson's disease: an update on recent developments.Semantic proximity Read ↗

Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease.Semantic proximity Read ↗

Catalyzing a Cure: Discovery and development of LRRK2 inhibitors for the treatment of Parkinson's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.